News
03-30-2010, 11:05 PM
Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the United States and the European Union (EU). Eribulin, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai.
More... (http://www.news-medical.net/news/20100331/Eisai-seeks-simultaneous-approval-of-eribulin-mesylate-in-US-EU-and-Japan.aspx)
More... (http://www.news-medical.net/news/20100331/Eisai-seeks-simultaneous-approval-of-eribulin-mesylate-in-US-EU-and-Japan.aspx)